The median LC 50 of 18 leukemia drugs are shown for each individual molecular subtype. Low LC 50 values (that is, higher drug sensitivity) are shown in blue and high LC 50 values (that is, higher drug resistance) are shown in red. Circles with a dashed line indicate that only a single case with that subtype was tested for that drug. Missing/untested drugs are indicated as empty circles. With the exception of panobinostat, ruxolitinib, bortezomib and daunorubicin, the remaining 14 drugs demonstrated significant inter-subtype variability (P < 0.05 nominally and also after Benjamini-Hochberg correction).
